These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 20417387)
1. In response to Leppikangas H, et al, Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study. Lugassy DM; Stefan A; Dexeus D; Hoffman RS; Nelson LS Ann Emerg Med; 2010 May; 55(5):486; author reply 486-7. PubMed ID: 20417387 [No Abstract] [Full Text] [Related]
2. Levosimendan as a rescue drug in experimental propranolol-induced myocardial depression: a randomized study. Leppikangas H; Ruokonen E; Rutanen J; Kiviniemi V; Lindgren L; Kurola J Ann Emerg Med; 2009 Dec; 54(6):811-817.e1-3. PubMed ID: 19766354 [TBL] [Abstract][Full Text] [Related]
3. Is levosimendan better than dobutamine in acute heart failure in patients on beta-blockade treatment? What is the evidence? Omerovic E; Waagstein F; Swedberg K Eur J Heart Fail; 2010 Apr; 12(4):313-4. PubMed ID: 20335348 [No Abstract] [Full Text] [Related]
4. Levosimendan use in several scenarios of acute heart failure. Tavares M; Andrade AC; Mebazaa A Arq Bras Cardiol; 2008 Mar; 90(3):211-5. PubMed ID: 18392402 [TBL] [Abstract][Full Text] [Related]
5. Correspondence concerning the article: is levosimendan better than dobutamine in acute heart failure in patients on beta blockade treatment? What is the evidence? Wikström BG Eur J Heart Fail; 2010 Aug; 12(8):893. PubMed ID: 20675671 [No Abstract] [Full Text] [Related]
8. Levosimendan reduces plasma amino terminal proBNP in patients with decompensated heart failure. Mueller T; Gegenhuber A; Haltmayer M Int J Cardiol; 2005 Oct; 104(3):355-6; author reply 357-8. PubMed ID: 15950299 [No Abstract] [Full Text] [Related]
9. Levosimendan: The current situation and new prospects. Moreno N; Tavares-Silva M; Lourenço AP; Oliveira-Pinto J; Henriques-Coelho T; Leite-Moreira AF Rev Port Cardiol; 2014 Dec; 33(12):795-800. PubMed ID: 25459636 [TBL] [Abstract][Full Text] [Related]
10. [Acute hemodynamic and clinical effects of a new inotropic agent, levosimendan, in patients with severe heart failure]. Porcu M; Orrù P Ital Heart J Suppl; 2001 Feb; 2(2):205-6. PubMed ID: 11255888 [No Abstract] [Full Text] [Related]
11. Levosimendan therapy in decompensated chronic heart failure: favourable haemodynamic and neurohormonal effects but for how long? Parissis JT; Farmakis D; Kremastinos DT Eur J Heart Fail; 2006 Mar; 8(2):215; author reply 218. PubMed ID: 16442844 [No Abstract] [Full Text] [Related]
16. Levosimendan in patients with decompensated heart failure. Rosa EM; Osório AP; Scopel L Arq Bras Cardiol; 2008 Aug; 91(2):119. PubMed ID: 18709265 [No Abstract] [Full Text] [Related]
17. Levosimendan does not improve cardiac output or blood pressure in a rodent model of propranolol toxicity when administered using various dosing regimens. Kalam Y; Graudins A Int J Toxicol; 2012 Mar; 31(2):166-74. PubMed ID: 22422349 [TBL] [Abstract][Full Text] [Related]
19. Patients with advanced heart failure and the effects of levosimendan. Song ZZ; Ma J Am J Cardiol; 2007 Aug; 100(4):742; author reply 742-3. PubMed ID: 17697841 [No Abstract] [Full Text] [Related]
20. How to treat acute decompensated heart failure in the 'beta-blocker era'? Marcondes-Braga FG; Mangini S; Ayub-Ferreira SM; Bocchi EA; Bacal F Eur J Heart Fail; 2010 Aug; 12(8):893-4. PubMed ID: 20675672 [No Abstract] [Full Text] [Related] [Next] [New Search]